Agree Realty Corporation logo

Agree Realty Corporation (ADC)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
67. 04
+0.48
+0.7212%
$
7.92B Market Cap
- P/E Ratio
1.01% Div Yield
1.34M Volume
- Eps
$ 66.56
Previous Close
Add Transaction
Day Range
66.38 67.06
Year Range
64.43 82.08
Want to track ADC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Should You Buy This Millionaire-Maker Stock Instead of Agree Realty?

Should You Buy This Millionaire-Maker Stock Instead of Agree Realty?

Agree Realty (ADC 1.05%) has been a popular stock in 2024, with a share price gain of more than 15%. That's roughly three times the return of the average real estate investment trust (REIT).

Fool | 1 year ago
Earn Money While You Sleep With Monthly Dividends From These Stocks

Earn Money While You Sleep With Monthly Dividends From These Stocks

Interested in the stock market, but don't want to worry about chasing market gains?

247wallst | 1 year ago
Buy The Dip: 2 REITs Getting Way Too Cheap

Buy The Dip: 2 REITs Getting Way Too Cheap

Some REITs suffered a dip in recent weeks. As a result, they have become cheap again. We highlight 2 of our favorite buy-the-dip opportunities.

Seekingalpha | 1 year ago
Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Mersana Therapeutics is developing novel antibody-drug conjugates targeting a heretofore untapped immune checkpoint, as well as HER2 from another angle. The company has an operational runway of 6-7 quarters excluding collaboration revenues. The promise of phase 1 trial data gives us a chance to see if Mersana's ADC platform can make drugs that are more tolerable than those being developed by competitors.

Seekingalpha | 1 year ago
December's 5 Dividend Growth Stocks With 4.51%+ Yields

December's 5 Dividend Growth Stocks With 4.51%+ Yields

Dividend growth stocks, though not often the most exciting, can offer the potential for growing wealth and passive income over the long run. Every month, we screen for potential opportunities, starting with initial parameters, including dividend safety, growth, and consistency. Of course, further due diligence is essential; these initial screenings are just that “initial” and highlight potential names worth considering further but require further due diligence.

Seekingalpha | 1 year ago
2 REITs To Add To Your Christmas List And When To Buy For A Margin Of Safety

2 REITs To Add To Your Christmas List And When To Buy For A Margin Of Safety

Agree Realty and VICI Properties are high-quality REITs with strong fundamentals and impressive total returns, but currently offer little margin of safety due to their run-up in share prices. Investing with a margin of safety helps manage market volatility; for example, my cost basis of $53 for Realty Income has helped me stomach volatility and the stock's underperformance. I recommend assigning stocks specific roles in your portfolio; for example, Starwood Property for stable dividends, PepsiCo for moderate growth, and Visa for high growth, balancing income and growth.

Seekingalpha | 1 year ago
Is Agree Realty a Millionaire Maker?

Is Agree Realty a Millionaire Maker?

Net lease real estate investment trust (REIT) Agree Realty (ADC 1.39%) has a 4.1% dividend yield. That yield is a little higher than the 3.7% average for the REIT sector, but below the 5.6% you could get from buying industry leading net lease REIT Realty Income.

Fool | 1 year ago
What I Wish I Knew Before Investing In REITs

What I Wish I Knew Before Investing In REITs

I have done well over time, but I could have done even better. I have made many mistakes over the years. I discuss 3 of my biggest regrets as a REIT investor.

Seekingalpha | 1 year ago
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034.

Seekingalpha | 1 year ago
2 REITs To Buy After The Rally

2 REITs To Buy After The Rally

REITs are up 40% on average over the past year. But some individual REITs are not up at all. I discuss 2 REITs that remain heavily discounted.

Seekingalpha | 1 year ago
3 Durable Dividend Stocks to Buy for a Lifetime of Passive Income

3 Durable Dividend Stocks to Buy for a Lifetime of Passive Income

Some dividends are more durable than others. That's due to a combination of the underlying company's financial strength and the resiliency of its business model.

Fool | 1 year ago
My Single Biggest Regret As A REIT Investor

My Single Biggest Regret As A REIT Investor

I have outperformed REIT sector averages over the long run. But I could have done even better. I discuss my #1 biggest mistake I have made as a REIT investor.

Seekingalpha | 1 year ago
Loading...
Load More